subscribe
 

Experimental cell lines introduced

25th January 2019


AMS Bio has added new experimental cell lines to its CAR T cell research range. 

Recent FDA approval of CAR T cells for treatment of leukemia and lymphoma has resulted in rapid growth in research on the therapeutic uses of such cells. The new experimental cell lines provide the power to screen antibodies and ligands against a target, enhancing the search for new CAR T therapies.

A therapeutic Chimeric Antigen Receptor (CAR) is a transmembrane protein designed with an extracellular domain based on an antibody single-chain variable fragment (scFv) and intracellular signalling domains derived from the TCR g chain, along with other costimulatory receptors. The scFv provides a specific binding domain that recognises target proteins on cancer cells. A patient’s own T cells are isolated and activated, then transfected with a gene expressing the CAR. This reprograms the T cells to identify and attack tumour cells expressing the target protein, creating personalised immune cells designed to specifically target the patient’s cancer.

New stable CHO recombinant cell lines are available for constitutively expressing full length human CD123, PSMA and ICOSL. Each stable clonal cell line was selected for different levels of expression to mimic different stages of cancer target cells with various CD123, PSMA or ICOSL expression levels.





Subscribe

Subscribe



Newsbrief

FREE NEWSBRIEF SUBSCRIPTION

To receive the Scientist Live weekly email NewsBrief please enter your details below

Twitter Icon © Setform Limited
subscribe